Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
NCT06482853Phase 1Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jan 2025
- Primary completion
- Mar 2029
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of angiotensin-(1-7) in obesity and hypertension (HTN) (2 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Muscle Sympathetic Nerve Burst Rate at 120 minutes and Brachial Artery Diameter at 120 minutes. Started Jan 2025; status: recruiting.
02
Drugs
angiotensin-(1-7)
03
Conditions
obesityhypertension (HTN)
Beyond the preview
Go deeper on NCT06482853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482853.